Bolt Biotherapeutics Inc BOLT
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-02-05 |
| Shares Out. | 1,920,000 |
| Website | boltbio.com/ ↗ |
| Phone | 13025310855 |
| Employees | 23 |
| Revenue | $26,000 |
| Gross Profit | $26,000 |
| Net Income | -$7.2M |
| Free Cash Flow | -$34.6M |
| Total Assets | $48.0M |
| Total Liabilities | $28.2M |
| Equity | $19.8M |
About Bolt Biotherapeutics Inc
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
Bolt Biotherapeutics Inc is a publicly traded company under the ticker symbol BOLT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
10 analysts (2026-07-01)